Pt Bundamedik Tbk · IDX:BMHS
Pt Bundamedik Tbk — Q1 2023 Earnings Presentation
22 slides from Pt Bundamedik Tbk's earnings presentation, May 2023
Slide 1: PT Bundamedik Tbk Analyst Meeting – 1Q23 Results
PT Bundamedik Tbk Analyst Meeting – 1Q23 Results May 2023 Disclaimer: Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary
Slide 2: Leading Provider in Specialized Healthcare Services since 1973
Leading Provider in Specialized Healthcare Services since 1973
Slide 3: Bundamedik Tbk (BMHS) Ecosystem
Bundamedik Tbk (BMHS) Ecosystem Expanding Presence RSIA Az Zahra 10 HOSPITALS + 2 CLINICS Women & Children Hospitals 10 IVF CLINICS PADANG PONTIANAK BATAM 31 LABORATORIES Bunda Hospitals PALEMBANG MAKASSAR CLINICS NETWORK 400++ (KLINIK PINTAR) YOGYAKARTA 126 FERTILITY CLINICS NETWORK (KFI) Jakarta D
Slide 4: 1Q23 Key Highlights
1Q23 Key Highlights 1 2 Hospital Revenue Flat IVF cycles 10% -2% vs 1Q22* vs 4Q22 -0.6% -0.4% +24% # of Outpatients -1% vs 1Q22 vs 4Q22 -18% # of IP Days -6% +26% -35% # of Surgeries # of Lab Tests +16% -28% 126 # of KFI 3 4 Improvement in Expanding Capacity Consolidated Gross Margin 55% +25% YoY #
Slide 5: 1Q23 Results
@punva fp Piagnes | morvieyi «= SSBGP Paiccunic ERE OBO Pax, Ts, SEYNCA
Slide 6: Financial & Operational Performance
Financial & Operational Performance Flat QoQ growth; Initiatives in place to improve performance Key Notes HIGHLIGHTS OF CONSOLIDATED RESULT 1 Core Business in 1Q23 4Q22 1Q23 QoQ (%) YTD Mar 22 YTD Mar 23 YoY (%) • Hospitals metrics: mostly grew in #Outpatients, #IP Admission and OPERATIONALS #surge
Slide 7: Hospitals Volume
Hospitals Volume # OUTPATIENTS Existing # IP ADMISSION Existing New Hospitals New Hospitals +8% 485.7 120.8 124.0 122.1 +16% 34.4 383.1 359.6 390.5 104.3 101.7 7.8 7.6 7.6 6.7 6.6 22.1 19.6 21.3 2.0 1.9 2.3 5.8 8.1 10.4 10.6 11.4 1.4 0.5 2019 2020 2021 2022 1Q22 2Q22 3Q22 4Q22 1Q23 2019 2020 2021 20
Slide 8: Financial Performance
Financial Performance Consolidated REVENUE EBITDA Core Revenue (Rp B) EBITDA Margin (Rp B,% Margin) Covid Revenue Non-Core EBITDA Core EBITDA 51% +13% 451 25% 419 24% 4% 385 26% 18% 266 96% 100% +13% 74% 90 100% 132 60 7 59 0 53 73 83 60 1Q20 1Q21 1Q22* 1Q23 1Q20 1Q21 1Q22* 1Q23 Note: *) proforma da
Slide 9: Balance Sheet
Balance Sheet Remains healthy CASH VS DEBT NET DEBT-TO-EBITDA (Rp B) (x) Net 418 -135 -216 225 270 Debt 876 2.2x 830 855 625 613 629 605 0.7x 0.8x 518 490 100 -0.6x -0.4x 2019 2020 2021 2022 1Q23 2019 2020 2021 2022 1Q23 AR Days WORKING CAPITAL DAYS Inventory Days 58 53 AP Days 46 43 39 29 29 30 28
Slide 10: IVF Cycles
IVF Cycles Higher Contribution from Outside Jakarta Customers # OF IVF CYCLES (‘000) Weak Jan-23 as doctors and patients took longer break, cycles improved in 1.59 1.55 Feb and Mar 1.53 1.54 1.41 1.39 1.38 1.36 1.18 Jakarta 60% 55% 53% Outside 40% 45% 47% Jakarta 2Q21 1Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4
Slide 11: 2023 Initiatives: Morula
2023 Initiatives: Morula Improve internal business process Enhanced Brand Morula Positioning Morula Dragon Baby Package Enlarge Target Market including in anticipation for Dragon year IVF Tourism in 2024 Expand Business Ecosystem Advance Technology Product
Slide 12: Diagnos: Rightsizing Capacity post Covid
Diagnos Rightsizing Capacity post Covid Covid # OF TESTS (‘000) • Close 8 underperforming outlets, 265 Non Covid 239 35% 170 214 11% 172 -8% bringing 31 outlets as of Mar-23 20% YoY Non Covid 22% 8% Test Volume 89% 65% 80% 78% 92% • Promising Genomic business, 1Q22 2Q22 3Q22 4Q22 1Q23 contributing 1
Slide 13: Strengthening Our Core
Strengthening Our Core @punva fp Piagnes | morvieyi «= SSBGP Paiccunic ERE OBO Pax, Ts, SEYNCA
Slide 14: Employing Advanced Technology
Employing Advanced Technology Higher Success Rate Morula Services Higher Pregnancy Higher Pregnancy Success Rate Success Rate 68% 46% Morula is the first to offer PGT-A test which led to >50% success rate vs. non- 43% PGT-A1) 27% Fertility Wellness Fertility Acupuncture PGT-A is the latest leading t
Slide 15: Strengthening Our COEs
Strengthening Our COEs GynROSE Clinic Robotic Surgery Bunda Neuro Center Eras NICU/PICU Laparoskopi Bunda Health Center RSM Oncology Bunda General Hospital Bunda Women & Children Hospital Jakarta Klinik Tumbuh Kembang Anak Bunda Endoscopy Center
Slide 16: Ensuring Standardised Quality Process
Ensuring Standardised Quality Process
Slide 17: 2023 Outlook
2023 Outlook @punva fp Piagnes | morvieyi «= SSBGP Paiccunic ERE OBO Pax, Ts, SEYNCA
Slide 18: 2023 Key Focus Area
2023 Key Focus Area 3 2 4 Improve the performance of 1 3 Optimize productivity and our newly acquired hospitals performance of our network: KFI (satellite clinics for Morula) and 1 Diagnos lab outlets 5 Continue with cost efficiency 2 Key Focus 4 Enhance our competitive edge initiatives to maintain
Slide 19: 2023 Strategy
2023 Strategy New Hospitals Cost efficiency Morula Diagnos • Financial optimization • Ideal BPJS case mix that would • Strengthen KFI performance to • Footprint expansion reviewed implemented through revenue and drive better revenue and margin enhance morula brand positioning across all outlets and
Slide 20: Our New Booking Platform
Our New Booking Platform New Booking Platform Children’s Vaccine Book * Antenatal Care Book * * ready by 2nd week of May 2023 20
Slide 21: 2023 Network Planning
2023 Network Planning RSIA Bunda Jakarta Renovation RSIA Bunda Dewata Bunda Morula Nusa Dua Building renewal & rejuvenation for our Fully operate as W&C Hospital in Mar23. Morula add presence in Bali area to cater signature hospital. Expect to finish early Type C hospital with 25 bed capacity. domes
Slide 22: THANK YOU
THANK YOU Disclaimer: Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary. Specific data in this presentation was obtaine